Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,964 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04424147 | Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML | completed | Phase 2 | 96 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT00866918 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia | completed | Phase 3 | 106 | Children's Oncology GroupNETWORK | 3 | Oct 25, 2022 | clinicaltrials |
| NCT01586455 | Human Placental-Derived Stem Cell Transplantation(HPDSC) | completed | Phase 1 | 43 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT01842672 | Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia(MITCL) | completed | Phase 1 / Phase 2 | 41 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT02581917 | Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia | completed | — | 14 | Wake Forest University Health SciencesOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT01700673 | Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS | completed | Phase 2 | 25 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT01472107 | Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy(APL0511) | completed | — | 69 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT01373515 | Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 12 | MendusINDUSTRY | 1 | Oct 10, 2022 | clinicaltrials |
| NCT02686593 | Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML | completed | Phase 2 | 50 | The University of Hong KongOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT02403310 | A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | completed | Phase 1 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT05563207 | Application of Health Education Path of Traditional Chinese Medicine Nursin | completed | N/A | 60 | Shijiazhuang Pingan HospitalOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT05541224 | A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic Markers | completed | — | 6,917 | PETHEMA FoundationOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT01555268 | Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT03455140 | A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)(PARC) | completed | Phase 1 / Phase 2 | 49 | University of BirminghamOTHER | 3 | Sep 2, 2022 | clinicaltrials |
| NCT02287233 | A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 94 | AbbVieINDUSTRY | 4 | Aug 29, 2022 | clinicaltrials |
| NCT02582359 | MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age | completed | Phase 1 | 39 | Massachusetts General HospitalOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT01119066 | HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies | completed | Phase 2 | 422 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT01168219 | Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2022 | clinicaltrials |
| NCT01253070 | Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2022 | clinicaltrials |
| NCT03723681 | Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 1 | 7 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04452604 | Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19(COVLA) | completed | — | 79 | French Innovative Leukemia OrganisationOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT03035422 | Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia(SET-HAPLO) | completed | N/A | 24 | Association for Training, Education, and Research in Hematology, Immunology, and TransplantationOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT01834248 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT01005277 | Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | completed | — | 2,000 | Children's Oncology GroupNETWORK | 1 | Jul 14, 2022 | clinicaltrials |
| NCT05456048 | Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML | completed | — | 231 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT05169307 | CPX-351 Real-World Effectiveness and Safety Study | completed | — | 147 | Jazz PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT02109744 | Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients(AML) | completed | Phase 1 / Phase 2 | 27 | University of RochesterOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT01093573 | Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 34 | Brenda Cooper, MDOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT02551718 | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia | completed | N/A | 34 | University of WashingtonOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT03848754 | Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia | completed | Phase 1 | 14 | Medical College of WisconsinOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT01303796 | A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia(SEAMLESS) | completed | Phase 3 | 482 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 12 | Jun 22, 2022 | clinicaltrials |
| NCT04788420 | Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML | completed | — | 456 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT03483324 | Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation | completed | Phase 1 | 10 | Angiocrine BioscienceINDUSTRY | 1 | May 31, 2022 | clinicaltrials |
| NCT02979366 | Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome | completed | Phase 1 | 38 | Institut de Recherches Internationales ServierOTHER | 4 | May 18, 2022 | clinicaltrials |
| NCT03429387 | PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia(PIPPIN) | completed | N/A | 147 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT02200978 | A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia | completed | Phase 4 | 176 | South China Children's Leukemia GroupOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT00450450 | Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases | completed | Phase 3 | 27 | Children's Oncology GroupNETWORK | 1 | Apr 28, 2022 | clinicaltrials |
| NCT03449745 | Immune Checkpoint Receptors in AML-Leukemic Initiating Cells(ICAML-LIC) | completed | — | 199 | University Hospital, BordeauxOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03563560 | A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia(AML) | completed | Phase 1 | 10 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT03787498 | A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | completed | Phase 1 | 22 | Opna Bio LLCINDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02566395 | Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies | completed | Phase 3 | 10 | Northwell HealthOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT00900809 | QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia | completed | Phase 1 | 7 | ImmunityBio, Inc.INDUSTRY | 1 | Apr 5, 2022 | clinicaltrials |
| NCT04014764 | Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy((ANSWer)) | completed | — | 119 | Notable LabsINDUSTRY | 3 | Apr 5, 2022 | clinicaltrials |
| NCT01411267 | AC220 for Children With Relapsed/Refractory ALL or AML | completed | Phase 1 | 24 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT00531232 | A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS) | completed | Phase 2 | 38 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT01683123 | Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT(BUFLU) | completed | — | 143 | Grupo Espanol de trasplantes hematopoyeticos y terapia celularOTHER | 0 | Mar 17, 2022 | clinicaltrials |
| NCT03985007 | CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT01433965 | Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | completed | Phase 1 | 16 | University of California, DavisOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT03719183 | Comparison of Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional Cytogenetic Analysis in AML | completed | — | 120 | Assiut UniversityOTHER | 1 | Mar 9, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Oct 26, 2022source: clinicaltrials